Copies of the announcements regarding the collaboration agreements with Calico and Infinity are available on AbbVie's website at www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents.
UK City Code
The Revised Full-Year 2014 GAAP guidance and Revised Third-Quarter 2014 GAAP guidance constitute profit forecasts under Rule 28 of the City Code on Takeovers and Mergers issued by the Panel on Takeovers and Mergers (the "Code").
In accordance with Rule 28.4(a) of the Code, the principal assumptions upon which the forecasts are based are included at Schedule 1 to this announcement. In accordance with Rule 28.4(b) of the Code, there is a clear distinction in Schedule 1 between assumptions which the Directors of AbbVie (or other members of AbbVie's management) can influence and those which they cannot influence.
The Revised Full-Year 2014 GAAP guidance and Revised Third-Quarter 2014 GAAP guidance have been reported on by PricewaterhouseCoopers LLP ("PwC"), the Company's reporting accountants, and by J.P. Morgan Limited ("J.P. Morgan"), the Company's financial advisers. Copies of their reports are included at Schedules 2 and 3 to this announcement. PwC and J.P. Morgan have given and not withdrawn their consent to publication of this announcement with the inclusion of their reports.
The Directors of AbbVie confirm that their previously issued Adjusted Full-Year 2014 Earnings Guidance and Adjusted Q3 Earnings Guidance remains valid, as the initial investment expense will be treated as a specified item, and that PwC and J.P. Morgan have confirmed that their reports issued in connection with Adjusted Full-Year 2014 Earnings Guidance and Adjusted Q3 Earnings Guidance in accordance with Rule 28.1 of the Code on June 23, 2014 and July 25, 2014 continue to apply with respect to that adjusted guidance. These
Copyright©2014 PR Newswire.
All rights reserved